The Discounted Cash Flow (DCF) valuation of Coherus BioSciences Inc (CHRS) is 3.24 USD. With the latest stock price at 1.70 USD, the upside of Coherus BioSciences Inc based on DCF is 90.7%.
Based on the latest price of 1.70 USD and our DCF valuation, Coherus BioSciences Inc (CHRS) is a buy. buying CHRS stocks now will result in a potential gain of 90.7%.
| Range | Selected | |
| WACC / Discount Rate | 7.5% - 9.7% | 8.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 2.87 - 4.25 | 3.24 |
| Upside | 68.6% - 150.2% | 90.7% |